HeartBeam Ranked Second Globally in Portable ECG Innovation

HeartBeam has been recognized as a Global IP and Technology Leader in Portable Cardiac Diagnostics by PatentVest's "Total Cardiac Intelligence" report. The medical-technology company ranked second worldwide in 12-lead ECG innovation among 243 firms analyzed, trailing only industry giant GE Healthcare in the comprehensive evaluation available at https://ibn.fm/ZuLCr.

The recognition underscores HeartBeam's growing influence in the next generation of cardiac monitoring technology and highlights the rapid maturation of the company's proprietary synthesis-ECG system. HeartBeam's intellectual property foundation was cited as a major reason for its high placement in the global rankings, demonstrating the strength of its technological approach to remote cardiac care.

HeartBeam's system captures the heart's electrical signals in three noncoplanar dimensions and synthesizes them into a 12-lead ECG, representing a significant advancement in portable cardiac diagnostics. This unique approach allows physicians to obtain comprehensive cardiac data from patients outside traditional medical facilities, potentially transforming how cardiac conditions are detected and monitored.

The HeartBeam System is a portable non-invasive recorder intended to record, store, and transfer a patient's 3-Lead electrocardiogram acquired from five electrodes. The device is designed for use by adult patients in either clinical settings or at home, though it does not conduct cardiac analysis itself. Instead, it can be used with ECG Viewer software for manual interpretation of non-life-threatening arrhythmias by healthcare professionals.

The company's 3D ECG technology received FDA clearance for arrhythmia assessment in December 2024, while its 12-Lead ECG synthesis software remains under FDA review. HeartBeam holds over 20 issued patents related to technology enablement, providing a strong foundation for its position as a global innovator. Additional information about the company is available at https://ibn.fm/BEAT.

This recognition matters because it signals a significant shift in cardiac care accessibility. Portable ECG technology that can generate comprehensive 12-lead readings outside medical facilities could revolutionize how patients manage heart health, potentially enabling earlier detection of cardiac issues and reducing the need for hospital visits. For the healthcare industry, this represents progress toward more decentralized, patient-centered care models that could improve outcomes while potentially reducing costs.

The implications extend to millions of patients worldwide who require regular cardiac monitoring, particularly those with chronic conditions or those at risk of cardiac events. The ability to capture professional-grade ECG data at home could lead to more timely interventions and better long-term management of cardiac health. As the technology continues to evolve and gain regulatory approvals, it may fundamentally change the standard of care for cardiac patients globally.